Glaxosmithkline

This study aimed to check the long-term safety and effectiveness of an investigational drug called GSK1070806 for people with moderate-to-severe atopic dermatitis (eczema). It was an extension study for 79 participants who had already completed an earlier trial. The main goal was…

This study tested a new drug, GSK3915393, to see if it could slow the progression of idiopathic pulmonary fibrosis (IPF), a serious disease that causes permanent lung scarring and makes breathing difficult. About 158 people with IPF were randomly assigned to receive either the ne…

This study tested an injectable drug called GSK1070806 to see if it could reduce the severity of eczema (atopic dermatitis) in adults. It compared different doses of the drug against a placebo injection over 16 weeks. The main goal was to see how much the drug could reduce the ex…

This early-stage study aimed to find a safe and effective dose of a two-drug combination (niraparib and dostarlimab) for children and adolescents whose solid tumors returned or did not respond to standard treatments. It involved 47 young participants with cancers like osteosarcom…

This early-stage study tested a new combination of therapeutic vaccines in adults with chronic Hepatitis B who were already taking antiviral pills. The main goals were to check the safety of the vaccines and see if they could help the body's immune system fight the virus and redu…

This was a very early, first-in-human study to check if a new oral drug called GSK4172239D was safe and how it moved through the body in people with sickle cell disease. Only 11 participants received a single dose of either the drug or a placebo. The study was terminated early, a…

This study tested an investigational drug, GSK3858279, to see if it could safely reduce chronic nerve pain in adults with diabetes. About 147 participants received either the drug or a placebo injection for 12 weeks to compare pain relief. The trial was terminated early, and its …

This study aimed to find the best dose of an experimental drug, GSK3858279, to relieve moderate to severe pain from knee osteoarthritis. It involved 314 adults aged 40-80 and compared different doses of the drug against a placebo over 12 weeks. The trial was terminated early, and…